Cargando…
Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study
BACKGROUND: ABL-class and JAK-STAT signaling pathway activating alterations have been associated with both a poor post-induction minimal residual disease (MRD) response and an inferior outcome in B-cell acute lymphoblastic leukemia (B-ALL). However, in most of the studies patients received non-unifo...
Autores principales: | Norvilas, Rimvydas, Dirse, Vaidas, Semaskeviciene, Ruta, Mickeviciute, Orinta, Gineikiene, Egle, Stoskus, Mindaugas, Vaitkeviciene, Goda, Rascon, Jelena, Griskevicius, Laimonas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006339/ https://www.ncbi.nlm.nih.gov/pubmed/33781217 http://dx.doi.org/10.1186/s12885-020-07781-6 |
Ejemplares similares
-
Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion
por: Stukaite-Ruibiene, Egle, et al.
Publicado: (2022) -
HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia
por: Vitkevičienė, Aida, et al.
Publicado: (2019) -
Corrigendum to “HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia”
por: Vitkevičienė, Aida, et al.
Publicado: (2020) -
Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission
por: Borutinskaitė, Veronika, et al.
Publicado: (2022) -
Therapeutic Plasma Exchange in Multiple Sclerosis Patients with Abolished Interferon-beta Bioavailability
por: Giedraitiene, Natasa, et al.
Publicado: (2015)